

ACURA PHARMACEUTICALS, INC  
Form 8-K  
April 12, 2016

UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

---

FORM 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934**

**April 12, 2016**

Date of Report (Date of earliest event reported)

---

**ACURA PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

---

|   |                          |  |
|---|--------------------------|--|
| State of New York                                 | 1-10113                  | 11-0853640                                 |
| (State of Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification Number) |

616 N. North Court, Suite 120

Palatine, Illinois 60067

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

(Address of principal executive offices) (Zip Code)

**(847) 705-7709**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

**Item 8.01 Other Events**

On April 12, 2016 we issued a press release announcing that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of LTX-04, Acura's hydromorphone HCl tablets utilizing its oral abuse deterrent LIMITX technology for the management of pain in patients where an opioid analgesic is appropriate. The press release is attached hereto and filed as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit Number Description**

99.1                      Press Release dated April 12, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ACURA PHARMACEUTICALS, INC.**

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: April 12, 2016

**Exhibit Index**

**Exhibit Number Description**

|      |                                    |
|------|------------------------------------|
| 99.1 | Press Release dated April 12, 2016 |
|------|------------------------------------|